Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

Overview
Date Founded

2013

Headquarters

255 State Street,9th floor,Boston, MA 02109

Type of Company

Public

Employees (Worldwide)

123

Industries

Biotechnology
Medical Products & Equipment

Company Description

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Contact Data
Trying to get in touch with decision makers at Pieris Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, President & Director

Senior Vice President, Chief Business Officer & General Counsel

Chief Development Officer & Senior Vice President

Senior Vice President & Chief Scientific Officer

Chief Medical Officer

Vice President & Head of Discovery & Alliance Management

Senior Vice President & Head-Business Development

Principal Accounting Officer, Senior Vice President & Chief Financial Officer

Vice President, Human Resources

Vice President, Respiratory Medicine

Board of Directors

Former President of Genzyme Europe & General Manager of Cardiovascular Business at Genzyme Corp.

Chief Executive Officer, President & Director at Pieris Pharmaceuticals, Inc.

Co-Founder, President & Chief Executive Officer at NextCure, Inc.

Executive Vice President & Chief Medical Officer at Deciphera Pharmaceuticals, Inc.

Director at Vatera Healthcare Partners

Advisor at Siamab Therapeutics, Inc.

Chief Medical Officer at Pieris Pharmaceuticals, Inc.

Former Vice President-Strategy, External Innovation & Science Policy at Sanofi

Paths to Pieris Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Pieris Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Aquilo Capital Management focuses on long/short investments in the stocks of companies in the life sciences and biotechnology sectors

Details Hidden

MS is an active growth-oriented investor and manages portfolios invested in global equity with a long-term outlook. The firm focuses on mid- and small-cap companies from the healthcare sector, including pharma, emerging pharma, biotech, genomics, medtech, drug delivery and e-health.MS uses computer models to continuously screen a selection of 700-800 listed companies as well as pre-IPOs for which they systematically collect data in a proprietary database. This information is completed by both in-house and third-party fundamental research

Recent Transactions
Details Hidden

Pieris Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Pieris Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Pieris Pharmaceuticals, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Transaction Advisors
Underwriter

Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock

Investment Advisor

Advised onPieris Pharmaceuticals, Inc. raised money in a private placement transaction

Managing Director, ECM

Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock

Professional

Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock

In-House Counsel

Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Chief Financial Officer at Foghorn Therapeutics, Inc.

Publicist

Managing Director at Solebury Trout LLC

Publicist

Vice President at MacDougall Advisors, Inc.

Clients

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Key Stats and Financials As of 2020
Market Capitalization
$281M
Total Enterprise Value
$82.7M
Earnings Per Share
$-0.68
Revenue
$29.3M
Net Profit
$-37.2M
EBITDA
$-31.8M
EBITDAMargin
-108.43%
Total Debt
$17M
Total Equity
$31M
Enterprise Value / Sales
2.82x
TEVNet Income
-2.22x
Debt TEV
0.21x
Three Year Compounded Annual Growth Rate Of Revenue
5.08%
Suppliers
Technical University of Munich Computer Software | Munich, Germany

TUM combines top-class facilities for cutting-edge research with unique learning opportunities for 37,343 students. TUM scientists are committed to finding solutions to the major challenges facing society as they move forward: Health & Nutrition Energy & Natural Resources Environment & Climate Information & Communications Mobility & Infrastructure. TUM thinks and acts with an entrepreneurial spirit. Its aim is ambitious: to create lasting value for society through excellence in education and research, the active promotion of next-generation talent and a strong entrepreneurial spirit. All of which combine to make TUM one of Europe's leading universities.

Enumeral Biomedical Holdings, Inc. Biotechnology | Arlington, MA

Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel antibody immunotherapies for the treatment of cancer and other diseases. It uses a human-driven immunoprofiling platform to identify and validate potential drug candidates in human immune microenvironments. The company was founded by Barry C. Buckland, John J. Rydzewski, Arthur H. Tinkelenberg in 2009 and is headquartered in Arlington, MA.

Sichuan Kelun Pharmaceutical Co., Ltd. IT Consulting & Services | Chengdu, Chn

Sichuan Kelun Pharmaceutical Co., Ltd. engages in research, development, manufacture, and sale of pharmaceutical products. Its products include large volume injection (infusion), small capacity injection (water injection), sterile powder injection, tablets, capsules, granules, oral solution, and peritoneum. It also provides dialysate and antibiotic intermediates, raw materials, pharmaceutical packaging materials, medical equipment, and other medical products. The company was founded by Ge Xin Liu in 1996 and is headquartered in Chengdu, China.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

MacroGenics, Inc. Pharmaceuticals - Rockville, MD

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Pieris Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Pieris Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Pieris Pharmaceuticals, Inc..